Akston Biosciences Corporation: Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster
Up to 600 volunteers will participate in an AKS-452 COVID booster study in the Netherlands to investigate boosting the immune response of those previously vaccinated with EMA-registered vaccines
Linda Pendergast Todd Zion Schelto Kruijff Kostenloser Wertpapierhandel Johnson Janssen Akston Biosciences
Source: finanznachrichten.de